Step Pharma Establishes Scientific Advisory Board

Paris, France, 25th February 2018 – Step Pharma, a company focused on the development new oral treatments of a range of autoimmune diseases today announced the establishment of a Scientific Advisory Board to help guide the development of the company’s products.

“Step Pharma is dedicated to bringing clinical demonstration of CTPS1 inhibitors’ value for patients in range of diseases, starting with auto-immune disorders,”said Tim Bourne, CSO of Step Pharma. “We have assembled world experts in immunology and translational medicine to guide the company’s efforts. We look forward to many contributions from this distinguished group.”

Members of the Step Pharma Scientific Advisory Board include:

  • Christophe Benoist, M.D., PhD., Professor of Immunohematology at Harvard Medical School,
  • Alain Fischer, M.D., PhD, Professor at The College de France, scientific founder of Step Pharma,
  • Iain McInnes, M.D., PhD, Head of Division of Immunology, Infection and Inflammation in the Faculty of Medicine based in Glasgow (UK) Royal Infirmary, Professor of Rheumatology,
  • Tim Wright, M.D., PhD, Chief Research and Development Officer of Regulus Therapeutics Inc.

 

About Step Pharma

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of autoimmune diseases. The company has identified several series of CTPS1 inhibitors, with the most advanced series currently undergoing lead optimization.

Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Dr Sylvain Latour’s laboratory and Prof. Alain Fischer (UMR1163 Inserm unit). Step Pharma is based in Paris, France. More information on the company can be found at www.step-ph.com.


Step Pharma Completes €14.5 million Series A Financing with Additional New Investor

Proceeds to Support Advancement of First-in-class Immunomodulators for Autoimmune Diseases towards Clinical Studies

Paris, France, 21 November 2017 – Step Pharma today announced the closing of a Series A financing totalling €14.5 million. Pontifax joined existing investors led by Kurma Partners, and including Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares), Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute in an €8.6 million second closing of the round.

The additional proceeds will be used to advance the company’s novel class of oral immunomodulators targeting cytidine triphosphate synthase 1 (CTPS1) to clinical studies. CTPS1 is a novel target discovered at the Imagine Institute (Paris, France) in rare genetic disease patients exhibiting deficiency in this enzyme involved in CTP nucleotide production.

“There is a long, established history of using nucleotide synthesis inhibitors to treat autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis or psoriasis, but their clinical use is limited due to lack of tissue selectivity. Targeting CTPS1 should allow selective modulation of specific immune cell populations, such as T and B cells, without affecting other tissues, which should translate to better efficacy and an improved therapeutic index,” said Geoffroy de Ribains, CEO and co-founder of Step Pharma. “Our funding to date has enabled us to build a proprietary assay platform, discover first series of CTPS1 compounds and show initial proof of concept in vivo. With the continued support of our investors and new investor Pontifax, we will be able to advance our CTPS1 program into clinical testing.”

“Step Pharma is exploring a completely new paradigm for the treatment of autoimmune diseases. The rare combination of a clinically validated target, a novel mechanism of action, and a significant unmet medical need led us to create the company with the Imagine Institute and Sygnature Discovery, and we are excited to see the program progress. The ability of Step Pharma to attract Pontifax confirms the potential of this approach,” said Vanessa Malier of Kurma Partners.

Targeting CTPS1

Cytidine nucleotide triphosphate (CTP) is a precursor required for several key processes involved in cell division.

It originates from two sources: a salvage pathway and a de novo synthesis pathway that depends on several enzymes, including CTPS1.

Importantly, patients deficient in CTPS1 only exhibit certain immunodeficiencies without other clinical problems, strongly suggesting a predominant and key role of CTPS1 in selected immune cell populations. CTPS1 therefore represents a therapeutic target for a new class of highly selective immunomodulatory drugs.

About Step Pharma

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of autoimmune diseases. The company has identified several series of CTPS1 inhibitors, with the most advanced series currently undergoing lead optimization.

Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Dr Sylvain Latour’s laboratory and Prof. Alain Fischer (UMR1163 Inserm unit). Step Pharma is based in Paris, France. More information on the company can be found at www.step-ph.com.

Download as PDFDownload French version